DEF: Integrated BioPharma Sets 2025 Annual Meeting Agenda

Integrated BioPharma, Inc. announces its 2025 Annual Meeting to address director election, executive compensation, and auditor ratification.

Summary

• The 2025 Annual Meeting of Stockholders will be held on December 1, 2025, at 9:00 a.m. local time, at the company's executive offices in Hillside, New Jersey.
• Stockholders will vote on the election of the Class III director, Eric Friedman, for a three-year term expiring at the 2028 Annual Meeting.
• A non-binding, advisory vote on executive compensation and its frequency (one, two, or three years) will be conducted; the Board recommends a three-year frequency.
• Stockholders will also vote to ratify the appointment of CBIZ CPAs P.C. as the independent auditor for the fiscal year ending June 30, 2026.
• The record date for voting is October 17, 2025, with 31,059,610 shares of Common Stock outstanding and entitled to vote.
• Net income significantly increased from a loss of $34,000 in fiscal year 2023 to a profit of $112,000 in fiscal year 2024, and further to $808,000 in fiscal year 2025.
• Total Shareholder Return (TSR) was $72 in 2025, compared to $42 in 2024 and $66 in 2023.
• Executive compensation for Co-CEOs Christina Kay and Riva Sheppard, and CFO Dina Masi, decreased in fiscal year 2025 compared to fiscal year 2024, primarily due to lower option awards value.
• The company's independent auditor changed from Marcum, LLP to CBIZ CPAs P.C. effective April 24, 2025, following CBIZ's acquisition of Marcum's attest business; no disagreements were reported.
• The Board of Directors unanimously recommends voting FOR all proposals, including the election of Eric Friedman, a three-year frequency for executive compensation votes, approval of executive compensation, and ratification of CBIZ CPAs P.C. as auditor.

Sentiment

Score: 7

Explanation: The significant increase in net income is a strong positive, indicating improved financial health. However, the decline in TSR in 2024 and some corporate governance weaknesses, such as a non-independent audit committee member and lack of a formal nominating committee, temper the overall positive sentiment.

Positives

• Net income increased substantially from $112,000 in fiscal year 2024 to $808,000 in fiscal year 2025, indicating improved financial performance.
• Executive bonuses for named executive officers increased by approximately 34% in fiscal year 2025 compared to the prior year, reflecting achievement of quantitative and qualitative goals.
• The Board of Directors unanimously recommends voting in favor of all proposals, suggesting internal alignment on key governance and operational matters.
• The company has adopted an Insider Trading Policy to promote ethical conduct and compliance with securities laws.

Negatives

• Total Shareholder Return (TSR) experienced a decline from $66 in 2023 to $42 in 2024, before recovering to $72 in 2025, indicating some volatility in shareholder value.
• Executive compensation for Co-CEOs and the CFO decreased in fiscal year 2025 compared to fiscal year 2024, primarily due to lower option awards value.
• The Audit Committee includes one non-independent director, Mr. William Milmoe, who beneficially owns approximately 42.5% of the company's outstanding common stock.
• The Compensation Committee does not currently have a formal charter.
• The company does not have a standing nominating committee, with the entire Board performing this function due to a limited number of independent directors.
• There is no policy regarding the consideration of director candidates recommended by security holders or a policy with regard to diversity in considering director nominees.
• The company does not have a formal process for stockholders to send communications directly to the Board of Directors, citing infrequency of such communications.

Risks

• There can be no assurances that the company will be able to comply with the qualitative and quantitative requirements for continued quotation of its Common Stock on the OTCQX Best Market.
• The advisory vote on the frequency of executive compensation is non-binding, meaning the Board may decide on a different schedule than the option approved by stockholders.
• The advisory vote on executive compensation is non-binding, and while the Board will evaluate significant votes against, it is not obligated to take specific actions.
• The company is not listed on a national securities exchange (NYSE or NASDAQ) and therefore is not required to have a formal clawback policy for erroneously awarded compensation in the event of a financial restatement.

Future Outlook

The Board believes that a three-year frequency for the advisory vote on executive compensation will allow the company to focus on long-term compensation practices and provide sufficient time to respond to stockholder sentiments. The company aims to comply with OTCQX listing requirements, though no assurances can be given. The Board reserves the right to appoint a different independent registered public accounting firm at any time if deemed in the best interest of the company and its stockholders.

Management Comments

• "On behalf of the Board of Directors of Integrated BioPharma, Inc. (the Company), it is our pleasure to invite you to attend the Company’s 2025 Annual Meeting of Stockholders."
• "The Board of Directors unanimously recommends that the stockholders vote FOR the proposals to be presented to the Company’s stockholders at the meeting."
• "It is the opinion of the Board that the frequency of the stockholder vote on the executive compensation should be once every three years."
• "Our Board believes that our executive compensation program achieves these goals [attract, motivate, retain outstanding executives; align financial interests with stockholders]."

Industry Context

The company operates within the nutraceutical business, as evidenced by director Damon DeSantis's extensive experience in this sector, including his past role as CEO of Rexall Sundown Nutritional Company. The company's corporate governance practices are benchmarked against NASDAQ Stock Market definitions for director independence, despite not being listed on a national exchange, and it is quoted on the OTCQX Best Market, requiring compliance with specific qualitative and quantitative requirements. The change in independent auditor reflects broader industry consolidation, with CBIZ CPAs acquiring the attest business of Marcum, LLP.

Comparison to Industry Standards

• Director Damon DeSantis serves on the board of Celsius Holding, Inc., a public company and maker of a leading global fitness drink, and was previously CEO of Rexall Sundown Nutritional Company, a former Nasdaq 100 company, providing relevant industry expertise.
• Director William H. Milmoe is Chairman Emeritus of Celsius Holdings, Inc., a Nasdaq listed public company, offering experience from a comparable public entity.
• The company uses the definition of independence as defined by The NASDAQ Stock Market for its directors, even though its common stock is not listed on a national securities exchange.
• The company's lack of a formal clawback policy is noted as it is not listed on the New York Stock Exchange or the Nasdaq Stock Market, which typically mandate such policies.

Management Changes

Corporate Governance

Legal Proceedings

• None of the directors or executive officers have been involved in any legal proceedings in the past 10 years that would require disclosure.

Related Party Transactions

• Warehouse and office facilities are leased from Vitamin Realty Associates, L.L.C., which is 100% owned by the Estate of E. Gerald Kay, Riva Sheppard, and Christina Kay (Co-Chief Executive Officers and directors).
• The Third Lease Amendment, effective July 1, 2022, increased rentable square footage to 116,175 and provides for minimum annual rental payments of $842,000 plus increases in real estate taxes and building operating expenses.

Stakeholder Impact

• Shareholders will have the opportunity to vote on key governance matters, including director election, executive compensation, and auditor appointment, directly influencing the company's future direction and oversight.
• Employees, particularly executive officers, are impacted by the compensation program design, including base salary, bonuses, and equity awards, which are tied to performance and retention objectives.
• The company's ability to maintain its quotation on the OTCQX Best Market could impact liquidity and visibility for shareholders.
• The related party lease arrangements with Vitamin Realty Associates, L.L.C. represent ongoing financial commitments that directly benefit key management and their family members.

Next Steps

• Stockholders are urged to vote on the proposals for the 2025 Annual Meeting by December 1, 2025.
• The company will elect a Class III director for a three-year term expiring at the 2028 Annual Meeting.
• Stockholders will provide advisory votes on executive compensation and its frequency.
• The appointment of CBIZ CPAs P.C. as the independent auditor for the fiscal year ending June 30, 2026, will be ratified.
• Stockholders wishing to submit proposals for the 2026 Annual Meeting must do so by approximately November 27, 2025.

Key Dates

Recommendation

While the company demonstrated a significant improvement in net income for fiscal year 2025, which is a positive indicator, the mixed performance in Total Shareholder Return and certain corporate governance weaknesses (e.g., non-independent audit committee member, lack of formal nominating committee and clawback policy) suggest a 'hold' recommendation. The filing primarily focuses on procedural matters for the annual meeting and does not present new strategic initiatives or financial forecasts that would warrant a stronger 'buy' or 'sell' stance. Investors should monitor future financial performance and any improvements in governance practices.

Keywords

Proxy Statement, Annual Meeting, Corporate Governance, Executive Compensation, Auditor Ratification, Director Election, Integrated BioPharma, SEC Filing, Stockholder Vote, Financial Reporting